Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $190.099 thousand which beat the analyst consensus estimate of $156.500 thousand by 21.47 percent. This is a 69.48 percent decrease over sales of $622.849 thousand the same period last year.